The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2024 | The evolution of alloSCT in Richter’s transformation and its combination with biological agents
Issa Khouri, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the evolution of allogeneic stem cell transplantation (alloSCT) for patients with Richter’s transformation. Dr Khouri concludes that alloSCT remains the preferred treatment for these patients in 2024, especially when combined with emerging biological therapies. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
